Yabing Zheng
Shantou Central Hospital(CN)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, Estrogen and related hormone effects
Most-Cited Works
- → PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer(2024)133 cited
- → miR-181b promotes chemoresistance in breast cancer by regulating Bim expression(2015)68 cited
- → Down‐Regulation of Asparagine Synthetase Induces Cell Cycle Arrest and Inhibits Cell Proliferation of Breast Cancer(2014)48 cited
- → shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells(2014)33 cited
- → Construction of an mRNA-miRNA-lncRNA network prognostic for triple-negative breast cancer(2021)31 cited
- → Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling(2019)29 cited
- → Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study(2021)25 cited
- → Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial(2023)20 cited
- → Long non-coding RNA TPT1-AS1 sensitizes breast cancer cell to paclitaxel and inhibits cell proliferation by miR-3156-5p/caspase 2 axis(2021)19 cited
- → Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial(2024)17 cited